Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age
Gadopiclenol Pharmacokinetics, Safety and Efficacy in Pediatric Patients < 2 Years of Age
Sponsor: Guerbet
This PHASE2 trial investigates Body Indication and Central Nervous System Diseases and is currently completed. Guerbet leads this study, which shows 12 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Completed PHASE2
-
Apr 2025 — Sep 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Jun 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE2
-
Sep 2023 — Nov 2023 [monthly]
Recruiting PHASE2
-
Jun 2023 — Sep 2023 [monthly]
Recruiting PHASE2
-
Nov 2022 — Jun 2023 [monthly]
Recruiting PHASE2
First recorded
Sep 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Guerbet
For direct contact, visit the study record on ClinicalTrials.gov .